Search

A study led by researchers at Memorial Sloan Kettering and New York University has shown that TET2 loss enhances the function of blood stem cells, causing them to renew themselves more efficiently than normal blood stem cells.

… Saturday, October 1, 2011 Summary A study led by researchers at Memorial Sloan Kettering and New York University has shown that TET2 loss enhances the function of blood stem cells, causing them to renew themselves more efficiently than normal blood stem cells. In 2008, two research groups in Europe made

In 2023, the MSK Giving community raised a record-breaking $1 billion — 100% of which will support our mission of ending cancer for life.

… Monday, June 10, 2024 In 2023, the MSK Giving community raised a record-breaking $1 billion — 100% of which will support our Memorial Sloan Kettering Cancer Center (MSK) mission of ending cancer for life . Every single member of the MSK Giving community was key to this historic success. “We are the most

A large study that analyzed nearly 120,000 cells in a developing mouse embryo is full of surprises.

… Monday, April 8, 2019 Summary Scientists in the Sloan Kettering Institute have combined powerful laboratory and computational techniques to analyze the earliest moments of mouse development. The results could help explain why cancers form more commonly in certain places than in others. To a developmental

Take a look back at some of the biggest science stories from this past year.

… Tuesday, December 21, 2021 The aim of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering Cancer Center is to pursue the best biological science wherever it leads. This past year, SKI scientists made groundbreaking discoveries across the biomedical spectrum — from how proteins function at

On November 3, 2021, a panel of MSK doctors joined The Abyssinian Baptist Church for an educational webinar about COVID-19 vaccination.

… Thursday, November 11, 2021 On November 3, 2021, a panel of MSK doctors joined Linda Thompson, leader of the Abyssinian Baptist Church’s Health Ministry, in an educational webinar to discuss questions about COVID-19 vaccination and address common myths and misconceptions about the vaccine. The panel

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.

… Friday, August 2, 2024 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ® , also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called  synovial sarcoma . Afami-cel is the first engineered

A new imaging approach could shorten the time needed to determine whether a brain tumor treatment is working.

… Friday, July 13, 2018 Summary It is hard to monitor whether treatment for a brain tumor is having an effect. A new diagnostic technique called hyperpolarized MRI provides a clear image of the brain’s metabolic activity. This can give important clues about whether a treatment is working in a shorter time

Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. Memorial Sloan Kettering experts are involved in notable research presented at the meeting and are available to comment on topics including immunotherapy, precision medicine and targeted treatments, genomics, cancer interception and prevention, clinical trial design, cancer health disparities, and more. For more information and to set up interviews or access photos and video, contact [email protected] and [email protected].

… Thursday, March 28, 2019 Thousands of oncology experts from around the world will gather in Atlanta from March 29 – April 3 for the American Association for Cancer Research (AACR) Annual Meeting 2019. This year’s theme, “ Integrative   Cancer Science • Global Impact • Individualized Patient Care ,“ reinforces

A small interfering RNA implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival and objective response rate in patients with locally advanced pancreatic cancer with these mutations, according to results of a multisite, international phase 2 clinical trial led by Memorial Sloan Kettering Cancer Center.

… Thursday, January 29, 2026 A small interfering RNA (siRNA) implant targeting KRAS G12D/G12V mutations has shown a promising trend toward improved overall survival (OS) and objective response rate (ORR) in patients with locally advanced pancreatic cancer (LAPC) with these mutations, according to results

Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering's new cancer research facility, including a 23-story laboratory structure that opens this month. Mr. Zuckerman's donation is the largest single commitment by an individual in Memorial Sloan Kettering's history.

… Wednesday, May 10, 2006 Memorial Sloan Kettering Cancer Center (MSKCC) today announced a major commitment from publisher, real estate developer, and MSKCC Board member Mortimer B. Zuckerman of $100 million from his charitable trust toward Memorial Sloan Kettering’s new cancer research facility, including